<DOC>
	<DOCNO>NCT01746095</DOCNO>
	<brief_summary>The purpose study determine whether AeroVanc treatment safe effective reduce number MRSA colony form unit lung cystic fibrosis patient .</brief_summary>
	<brief_title>Efficacy Safety Study AeroVanc Treatment Persistent MRSA Lung Infection Cystic Fibrosis Patients</brief_title>
	<detailed_description>This Phase 2a randomize , multicenter , double-blind , placebo-controlled , parallel group study examine safety efficacy AeroVanc treatment persistent MRSA lung infection CF patient . Pharmacokinetics evaluate subgroup measure plasma sputum concentration vancomycin . Prior treatment , patient randomize receive either AeroVanc twice daily ( bid ) , placebo bid . Patients stratify base presence Pseudomonas aeruginosa ( P. aeruginosa ) co-infection treat chronic suppression regimen . Patients P. aeruginosa co-infection chronic inhale suppression regimen ( nothing patient consider stable opinion investigator despite lack treatment ) . Regardless treatment regimen , month , screen schedule AeroVanc placebo administration give time . Patients month screen AeroVanc placebo administration period coincides treatment cycle TOBI ( e.g. , Cayston colistin ) . All patient must least 24-hour washout period stop anti-Pseudomonas therapy prior Visit 2 ( Baseline ) pre-dose microbiology sputum sample . The AeroVanc placebo treatment duration 28 day , efficacy safety parameter measure , patient follow 56 day . There two treatment cohort study , comprise 40 randomize ( 1:1 active placebo ) treat patient ( adult ≥18 child ≥12 year age ) . In Cohort 1 , patient enrol randomized receive 32 mg dose AeroVanc bid placebo bid . Prior start enrollment Cohort 2 , safety evaluation carry Data Monitoring Committee ( DMC ) base treatment data first 20 patient Cohort 1 . Subject Sponsor 's write communication DMC 's opinion acceptable safety , dose active arm Cohort 2 escalate 64 mg bid . Optionally , active arm Cohort 2 may also keep ( 32 mg bid ) , reduce 16 mg bid , depend outcome DMC 's safety evaluation .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<criteria>1 . Adults ≥18 year old ( legally authorize representative child ≥12 &lt; 18 year old ) : Able communicate site personnel understand voluntarily sign Informed Consent Form ( ICF ) . Children ≥12 &lt; 18 year old : Able communicate site personnel understand voluntarily sign Assent Form . 2 . Able willing comply protocol , include availability schedule study visit . 3 . Have confirm diagnosis CF , determine clinical feature consistent CF phenotype , plus one following : ) Positive sweat chloride test ( value ≥60 mEq/L ) , b ) Genotype two mutation consistent CF ( ie , mutation cystic fibrosis transmembrane conductance regulator [ CFTR ] gene ) . 4 . Be ≥12 year old time ICF/Assent Form signing . 5 . Have sputum culture positive MRSA Screening , least 10,000 CFUs/mL MRSA . 6 . In addition screen sample , least two historical respiratory tract culture ( i.e. , sputum and/or throat swab ) positive MRSA prior Screening evidence MRSA lung infection persist least 6 month prior Screening . 7 . Have force expiratory volume 1 second ( FEV1 ) ≥30 % ≤100 % predicted normalized age , gender , height Screening . 8 . Evidence , define one following , persistent MRSA lung infection suspect cause health consequence . Have least one episode acute pulmonary infection treat nonmaintenance antibiotic within 12 month Screening . Initiation treatment intermittent inhale antiPseudomonas therapy qualify treatment nonmaintenance antibiotic . Requires antiMRSA treatment part maintenance regimen prevent pulmonary exacerbation respiratory symptom . 9 . Be able perform technique necessary use AeroVanc inhaler measure lung function . 10 . Be able produce expectorate sputum sample able willing undergo standardize sputum induction . 11 . Agree smoke Screening end study . 12 . Female patient childbearing potential eligible participate study NOT pregnant lactating , patient use highly effective method birth control . 13 . Patients P. aeruginosa coinfection must either stable regular suppression regimen inhale antibiotic must , opinion investigator , stable despite lack treatment . Patients Cayston base therapy must receive least 2 cycle Cayston prior Baseline ( 2 consecutive month 2 cycle 4 month ) . 1 . Administration investigational drug device within 28 day prior ICF/Assent Form signing . 2 . Use iv inhale antiMRSA drug within 28 day oral antiMRSA drug within 14 day prior Visit 2 ( ie , randomization , Baseline AeroVanc/placebo treatment initiation ) . 3 . A history previous allergy sensitivity vancomycin , component ( ) study drug placebo except history redman syndrome . 4 . History severe cough/bronchospasm upon inhalation dry powder inhalation product , nebulized vancomycin . 5 . Resistance vancomycin Screening ( vancomycin resistant Staphylococcus aureus [ VRSA ] , vancomycin intermediate resistant Staphylococcus aureus [ VISA ] , minimum inhibitory concentration [ MIC ] ≥4 mcg/mL ) . 6 . Oral corticosteroid dose exceed 10 mg prednisone per day 20 mg prednisone every day , equipotent dose another corticosteroid . 7 . History sputum culture throat swab culture yield B. cepacia gladioli previous two year , nontuberculosis mycobacteria previous six month . 8 . An acute upper low respiratory infection , pulmonary exacerbation within 7 day prior Randomization . 9 . Changes antimicrobial , bronchodilator , antiinflammatory corticosteroid medication within 7 day prior ICF/Assent Form signing . 10 . Current daily continuous oxygen supplementation requirement 2 L/min night . 11 . Changes physiotherapy technique schedule within 7 day prior ICF/Assent Form signing . 12 . History lung solid organ transplantation currently list receive lung solid organ transplantation . 13 . A chest XRay Screening abnormality indicate significant acute finding ( eg , pneumothorax , pleural effusion ) . 14 . Lactating female female positive pregnancy test result . All woman childbearing potential test . 15 . Renal insufficiency , define creatinine clearance &lt; 50 mL/min use CockcroftGault equation adult Schwartz equation child , Screening . 16 . Diagnosed clinically significant hearing loss . 17 . Abnormal liver function , define ≥4x upper limit normal ( ULN ) , serum aspartate aminotransferase ( AST ) serum alanine aminotransferase ( ALT ) , know cirrhosis time Screening . 18 . Serum hematology chemistry screen result judgment Investigator would interfere completion study . 19 . Positive human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . 20 . Other finding medical history screening , Investigator 's opinion , would compromise safety patient quality study data .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>MRSA</keyword>
	<keyword>Methicillin-resistant Staphylococcus aureus</keyword>
	<keyword>Lung infection</keyword>
	<keyword>AeroVanc</keyword>
	<keyword>Vancomycin</keyword>
</DOC>